NASDAQ: BCTX |
| Healthcare / Biotechnology / Canada |
6.23 | +0.6200 | +11.05% | Vol 1.16M | 1Y Perf -5.56% |
Jun 24th, 2022 16:00 DELAYED |
BID | 6.23 | ASK | 6.30 | ||
Open | 5.67 | Previous Close | 5.61 | ||
Pre-Market | - | After-Market | 6.17 | ||
- - | -0.06 -0.96% |
Target Price | 20.00 | Analyst Rating | Strong Buy 1.00 | |
Potential % | 221.03 | Finscreener Ranking | — - | |
Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
Price Range Ratio 52W % | 25.80 | Earnings Rating | — | |
Market Cap | 95.19M | Earnings Date | 5th Jul 2022 | |
Alpha | 9.78 | Standard Deviation | 72.13 | |
Beta | -48.54 |
Today's Price Range 5.676.38 | 52W Range 4.0612.47 | 5 Year PE Ratio Range -3.50-1.10 |
Summary:
Buy
Technical Indicators: | Buy |
Moving Averages: | Buy |
Performance | |||
---|---|---|---|
1 Week | 11.45% | ||
1 Month | 28.72% | ||
3 Months | -35.24% | ||
6 Months | -33.01% | ||
1 Year | -5.56% | ||
3 Years | - | ||
5 Years | - | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -42.39 | |||
ROE last 12 Months | -44.52 | |||
ROA (5Y Avg) | -6.26 | |||
ROA last 12 Months | -41.48 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -46.77 | |||
Return on invested Capital Q | -10.43 | |||
Return on invested Capital Y | -1.43 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-3.10 | ||||
1.95 | ||||
- | ||||
- | ||||
-8.10 | ||||
-0.98 | ||||
1.96 | ||||
2.95 | ||||
33.30M | ||||
Forward PE | - | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
121.60 | ||||
126.20 | ||||
0.00 | ||||
0.00 | ||||
180.70 | ||||
Leverage Ratio | 1.00 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.00 | ||||
0.00 | ||||
- | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2022 | -0.19 | -0.32 | -68.42 |
Q02 2022 | -0.17 | -0.24 | -41.18 |
Q04 2020 | - | -0.58 | - |
Q02 2020 | - | -1.99 | - |
Q03 2019 | - | -0.01 | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
Next Report Date | 5th Jul 2022 |
Estimated EPS Next Report | -0.19 |
Estimates Count | 2 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 1.16M |
Shares Outstanding | 15.28K |
Shares Float | 15.52M |
Trades Count | 7.48K |
Dollar Volume | 7.07M |
Avg. Volume | 546.95K |
Avg. Weekly Volume | 382.19K |
Avg. Monthly Volume | 409.30K |
Avg. Quarterly Volume | 849.36K |
BriaCell Therapeutics Corp. (NASDAQ: BCTX) stock closed at 6.23 per share at the end of the most recent trading day (a 11.05% change compared to the prior day closing price) with a volume of 1.16M shares and market capitalization of 95.19M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 0 people. BriaCell Therapeutics Corp. CEO is William Williams.
The one-year performance of BriaCell Therapeutics Corp. stock is -5.56%, while year-to-date (YTD) performance is -24.76%. BCTX stock has a five-year performance of %. Its 52-week range is between 4.06 and 12.47, which gives BCTX stock a 52-week price range ratio of 25.80%
BriaCell Therapeutics Corp. currently has a PE ratio of -3.10, a price-to-book (PB) ratio of 1.95, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -41.48%, a ROC of -46.77% and a ROE of -44.52%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from BriaCell Therapeutics Corp., there were 0 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.19 for the next earnings report. BriaCell Therapeutics Corp.’s next earnings report date is 05th Jul 2022.
The consensus rating of Wall Street analysts for BriaCell Therapeutics Corp. is Strong Buy (1), with a target price of $20, which is +221.03% compared to the current price. The earnings rating for BriaCell Therapeutics Corp. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BriaCell Therapeutics Corp. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BriaCell Therapeutics Corp. has a Buy technical analysis rating based on Technical Indicators (ADX : 49.69, ATR14 : 0.57, CCI20 : 91.33, Chaikin Money Flow : 0.07, MACD : 0.01, Money Flow Index : 62.28, ROC : 1.96, RSI : 56.26, STOCH (14,3) : 65.03, STOCH RSI : 0.78, UO : 46.92, Williams %R : -34.97), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BriaCell Therapeutics Corp. in the last 12-months were:
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies.
CEO: William Williams
Telephone: +1 604 921-1810
Address: 235 - 15th Street, Vancouver V7T 2X1, BC, CA
Number of employees: 0
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.